Theravasc
Biotechnology company developing repurposed drugs for vascular disease markets.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor | €0.0 | round | |
| investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
N/A | Debt | ||
| Total Funding | 000k | ||
Related Content
TheraVasc, Inc. is a privately held pharmaceutical company based in Ohio, specializing in the development of treatments for chronic medical conditions. The company is pioneering an oral formulation of sodium nitrite, with its flagship product, TV1001SR, aimed at treating peripheral artery disease (PAD) and diabetic neuropathy. PAD affects between 12-14 million people in the U.S., and there are currently no effective treatments available. TheraVasc's innovative approach seeks to improve blood flow to the extremities, offering a potential solution for millions of sufferers. The company primarily serves patients with chronic conditions, operating within the pharmaceutical and healthcare markets. TheraVasc's business model revolves around research and development, clinical trials, and eventual commercialization of its drug formulations. Revenue is generated through the sale of its pharmaceutical products once they receive regulatory approval.
Keywords: pharmaceutical, chronic diseases, sodium nitrite, TV1001SR, peripheral artery disease, diabetic neuropathy, Ohio, healthcare, innovation, clinical trials.